OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Proprietary cell lines offer opportunities for achieving high AAV titers.
In the ATMP space, CGTs are hitting their stride with unprecedented approvals in the past year alone.
March 06, 2024
Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.
March 04, 2024
March 02, 2024
Despite a growing number of biosimilar approvals, market uptake remains a challenge.
March 01, 2024
CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.
February 29, 2024
Webinar Date/Time: Thu, Mar 28, 2024 11:00 AM EDT
February 28, 2024
Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.
February 22, 2024
Daiichi Sankyo is investing approximately €1 billiion (US$1.08 billion) to expand its Pfaffenhofen an der Ilm, Germany, site for ADC development and production.
February 21, 2024
Webinar Date/Time: Wed, Mar 20, 2024 11:00 AM EDT
February 16, 2024
Webinar Date/Time: Thu, Mar 21, 2024 11:00 AM EDT